These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 21208846)
1. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. Camacho LH; Garcia S; Panchal AM; Lim J; Hong DS; Ng C; Madoff DC; Fu S; Gayed I; Kurzrock R Clin Colorectal Cancer; 2010 Dec; 9(5):311-4. PubMed ID: 21208846 [TBL] [Abstract][Full Text] [Related]
2. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Tsimberidou AM; Fu S; Ng C; Lim JA; Wen S; Hong D; Wheler J; Bedikian AY; Eng C; Wallace M; Camacho LH; Kurzrock R Cancer; 2010 Sep; 116(17):4086-94. PubMed ID: 20564148 [TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145 [TBL] [Abstract][Full Text] [Related]
4. Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases. Guan M; Chen SC; Ying HY; Zhao L; Li XY; Zhou JF; Shao YJ; Yang XD; Lin Y; Ning XH; Bai CM Chin Med J (Engl); 2012 Oct; 125(20):3640-5. PubMed ID: 23075717 [TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases. Boilève A; De Cuyper A; Larive A; Mahjoubi L; Najdawi M; Tazdait M; Gelli M; Tselikas L; Smolenschi C; Malka D; Pignon JP; Ducreux M; Boige V Eur J Cancer; 2020 Oct; 138():89-98. PubMed ID: 32871526 [TBL] [Abstract][Full Text] [Related]
6. Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure. Sato Y; Inaba Y; Ura T; Nishiofuku H; Yamaura H; Kato M; Takahari D; Tanaka T; Muro K J Gastrointest Cancer; 2018 Jun; 49(2):132-137. PubMed ID: 28058527 [TBL] [Abstract][Full Text] [Related]
7. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Messersmith WA; Jimeno A; Jacene H; Zhao M; Kulesza P; Laheru DA; Kahn Y; Spira A; Dancey J; Iacobuzio-Donahue C; Donehower RC; Carducci M; Rudek MA; Hidalgo M Clin Colorectal Cancer; 2010 Dec; 9(5):297-304. PubMed ID: 21208844 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. Li C; Gu Y; Zhao M; Yuan Y; Wang F; Wang Z; Li W; Luo H; Chen C; Chen G; Ding P; Wu X; Lu Z; Pan Z; Xu R; He Y; Wan D; Li Y Cancer Chemother Pharmacol; 2014 Nov; 74(5):1079-87. PubMed ID: 25217393 [TBL] [Abstract][Full Text] [Related]
9. Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. Pernot S; Pellerin O; Mineur L; Monterymard C; Smith D; Lapuyade B; Gallois C; Khemissa Akouz F; De Baere T; Tougeron D; Thirot-Bidault A; Audemar F; Simon M; Lecaille C; Louafi S; Lepage C; Ducreux M; Taieb J Dig Liver Dis; 2022 Mar; 54(3):324-330. PubMed ID: 35027324 [TBL] [Abstract][Full Text] [Related]
11. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. Kemeny N; Jarnagin W; Paty P; Gönen M; Schwartz L; Morse M; Leonard G; D'Angelica M; DeMatteo R; Blumgart L; Fong Y J Clin Oncol; 2005 Aug; 23(22):4888-96. PubMed ID: 16009951 [TBL] [Abstract][Full Text] [Related]
12. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Ducreux M; Ychou M; Laplanche A; Gamelin E; Lasser P; Husseini F; Quenet F; Viret F; Jacob JH; Boige V; Elias D; Delperro JR; Luboinski M; J Clin Oncol; 2005 Aug; 23(22):4881-7. PubMed ID: 16009952 [TBL] [Abstract][Full Text] [Related]
13. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157 [TBL] [Abstract][Full Text] [Related]
14. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Kemeny N; Capanu M; D'Angelica M; Jarnagin W; Haviland D; Dematteo R; Fong Y Ann Oncol; 2009 Jul; 20(7):1236-41. PubMed ID: 19233901 [TBL] [Abstract][Full Text] [Related]
15. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Goéré D; Deshaies I; de Baere T; Boige V; Malka D; Dumont F; Dromain C; Ducreux M; Elias D Ann Surg; 2010 Apr; 251(4):686-91. PubMed ID: 20224373 [TBL] [Abstract][Full Text] [Related]
16. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A; Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906 [TBL] [Abstract][Full Text] [Related]
17. Hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma. Melichar B; Ferko A; Krajina A; Rousková L; Dvorák J; Svébisova H; Neoral C; Köcher M; Malirová E; Paral J J BUON; 2012; 17(4):677-83. PubMed ID: 23335524 [TBL] [Abstract][Full Text] [Related]
18. Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer. Del Freo A; Fiorentini G; Sanguinetti F; Muttini MP; Pennucci C; Mambrini A; Pacetti P; Della Seta R; Lombardi M; Torri T; Cantore M In Vivo; 2006; 20(6A):743-6. PubMed ID: 17203759 [TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases. Neyns B; Van Nieuwenhove Y; Aerts M; Fontaine C; Vermeij J; Schallier D; Decoster L; De Mey J; Vandenbroucke F; Hoorens A; Delvaux G; De Gréve J Anticancer Res; 2006; 26(1B):611-9. PubMed ID: 16739329 [TBL] [Abstract][Full Text] [Related]
20. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. DʼAngelica MI; Correa-Gallego C; Paty PB; Cercek A; Gewirtz AN; Chou JF; Capanu M; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N Ann Surg; 2015 Feb; 261(2):353-60. PubMed ID: 24646562 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]